Your browser doesn't support javascript.
loading
Two-year outcomes of leadless vs. transvenous single-chamber ventricular pacemaker in high-risk subgroups.
Boveda, Serge; Higuera, Lucas; Longacre, Colleen; Wolff, Claudia; Wherry, Kael; Stromberg, Kurt; El-Chami, Mikhael F.
Afiliação
  • Boveda S; Clinique Pasteur, 45 Avenue de Lombez BP 27617, 31076 Toulouse Cedex 3, France.
  • Higuera L; Medtronic, Inc., Minneapolis, MN, USA.
  • Longacre C; Medtronic, Inc., Minneapolis, MN, USA.
  • Wolff C; Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
  • Wherry K; Medtronic, Inc., Minneapolis, MN, USA.
  • Stromberg K; Medtronic, Inc., Minneapolis, MN, USA.
  • El-Chami MF; Emory University School of Medicine, Atlanta, GA, USA.
Europace ; 25(3): 1041-1050, 2023 03 30.
Article em En | MEDLINE | ID: mdl-36757859
ABSTRACT

AIMS:

This study compares clinical outcomes between leadless pacemakers (leadless-VVI) and transvenous ventricular pacemakers (transvenous ventricular permanent-VVI) in subgroups of patients at higher risk of pacemaker complications. METHODS AND

RESULTS:

This study is based on the Micra Coverage with Evidence Development (CED) study. Patients from the Micra CED study were considered in a high-risk subgroup if they had a diagnosis of chronic kidney disease Stages 4-5 (CKD45), end-stage renal disease, malignancy, diabetes, tricuspid valve disease (TVD), or chronic obstructive pulmonary disease (COPD) 12 months prior to pacemaker implant. A pre-specified set of complications and reinterventions were identified using diagnosis and procedure codes. Competing risks models were used to compare reinterventions and complications between leadless-VVI and transvenous-VVI patients within each subgroup; results were adjusted for multiple comparisons. A post hoc comparison of a composite outcome of reinterventions and device complications was conducted. Out of 27 991 patients, 9858 leadless-VVI and 12 157 transvenous-VVI patients have at least one high-risk comorbidity. Compared to transvenous-VVI patients, leadless-VVI patients in four subgroups [malignancy, HR 0.68 (0.48-0.95); diabetes, HR 0.69 (0.53-0.89); TVD, HR 0.60 (0.44-0.82); COPD, HR 0.73 (0.55-0.98)] had fewer complications, in three subgroups [diabetes, HR 0.58 (0.37-0.89); TVD, HR 0.46 (0.28-0.76); COPD, HR 0.51 (0.29-0.90)) had fewer reinterventions, and in four subgroups (malignancy, HR 0.52 (0.32-0.83); diabetes, HR 0.52 (0.35-0.77); TVD, HR 0.44 (0.28-0.70); COPD, HR 0.55 (0.34-0.89)] had lower rates of the combined outcome.

CONCLUSION:

In a real-world study, leadless pacemaker patients had lower 2-year complications and reinterventions rates compared with transvenous-VVI pacing in several high-risk subgroups. TRIAL REGISTRATION ClinicalTrials.gov ID NCT03039712.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Doenças das Valvas Cardíacas / Falência Renal Crônica Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Europace Assunto da revista: CARDIOLOGIA / FISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Doenças das Valvas Cardíacas / Falência Renal Crônica Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Europace Assunto da revista: CARDIOLOGIA / FISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França